Amgen, Harvard Pilgrim Health Care sales and marketing update

Regional insurance company Harvard Pilgrim granted Repatha evolocumab from Amgen exclusive preferred status on its formulary in exchange for undisclosed discounts on the lipid-lowering drug. The parties also agreed to a pay-for-performance deal under which Amgen will provide Harvard Pilgrim with an “enhanced discount” if the reduction in LDL levels for Harvard Pilgrim members is less than what was observed during clinical trials. The size of the discount is not disclosed. Harvard Pilgrim will receive additional discounts if use of the drug exceeds undisclosed prespecified levels. ...